Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01
Vera B (1,2,3), Martínez-Vélez N (1,2,3), Xipell E (1,2,3), Acanda de la Rocha A (1,2,3), Patiño-García A (1,4), Saez-Castresana J (1,5), Gonzalez-Huarriz M (1,2,3), Cascallo M (6), Alemany R (7), Alonso MM (1,2,3).
(1) Navarra's Health Research Institute (IDISNA) Pamplona, Spain.
(2) Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, Pamplona, Spain.
(3) Dpt of Medical Oncology, University Hospital of Navarra, Pamplona 31008, Spain.
(4) Dpt of Pediatrics, University Hospital of Navarra, Pamplona 31008, Spain.
(5) Brain Tumor Biology Unit, University of Navarra School of Sciences, 31008 Pamplona, Spain.
(6) VCN Biosciences, Sant Cugat del Vallés, 08174 Barcelona, Spain.
(7) Translational Research Laboratory, IDIBELL-Institut Catalá d'Oncologia, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease.
In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro.
In vivo, in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.
CITATION PLoS One. 2016 Jan 25;11(1):e0147211. doi: 10.1371/journal.pone.0147211. eCollection 2016